WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 330153

CAS#: 87-89-8

Description: Myo-Inositol or simply inositol, is a carbocyclic sugar that is abundant in brain and other mammalian tissues, mediates cell signal transduction in response to a variety of hormones, neurotransmitters and growth factors and participates in osmoregulation It is a sugar alcohol with half the sweetness of sucrose (table sugar). It is made naturally in human beings from glucose. Each kidney makes 2g a day; so 4g a day total is made. Other tissues synthesize it too, and the highest concentration is in the brain where it plays an important role making other neurotransmitters, and some steroid hormones bind to their receptors.

Chemical Structure

CAS# 87-89-8

Theoretical Analysis

MedKoo Cat#: 330153
Name: Myo-Inositol
CAS#: 87-89-8
Chemical Formula:
Exact Mass:
Molecular Weight:
Elemental Analysis:

Price and Availability

Size Price Availability Quantity
500.0g USD 350.0 2 Weeks
1.0kg USD 650.0 2 Weeks
2.0kg USD 1050.0 2 Weeks
Bulk inquiry

Synonym: Myo-Inositol; Hexahydroxycyclohexane; Myoinositol; NSC 8101; Nucite; Phaseomannite; Phaseomannitol; Scyllite;

IUPAC/Chemical Name: (1R,2r,3S,4R,5s,6S)-cyclohexane-1,2,3,4,5,6-hexaol


InChi Code: InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H/t1-,2-,3-,4+,5-,6-

SMILES Code: [C@@H]1([C@@H]([C@H]([C@@H]([C@H]([C@H]1O)O)O)O)O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Mutlu N, Kumar A. Messengers for morphogenesis: inositol polyphosphate signaling and yeast pseudohyphal growth. Curr Genet. 2018 Aug 12. doi: 10.1007/s00294-018-0874-0. [Epub ahead of print] Review. PubMed PMID: 30101372.

2: Eid AH, El-Yazbi AF, Zouein F, Arredouani A, Ouhtit A, Rahman MM, Zayed H, Pintus G, Abou-Saleh H. Inositol 1,4,5-Trisphosphate Receptors in Hypertension. Front Physiol. 2018 Jul 26;9:1018. doi: 10.3389/fphys.2018.01018. eCollection 2018. Review. PubMed PMID: 30093868; PubMed Central PMCID: PMC6071574.

3: Laganà AS, Vitagliano A, Noventa M, Ambrosini G, D'Anna R. Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2018 Aug 4. doi: 10.1007/s00404-018-4861-y. [Epub ahead of print] Review. PubMed PMID: 30078122.

4: Uličná L, Paprčková D, Fáberová V, Hozák P. Phospholipids and inositol phosphates linked to the epigenome. Histochem Cell Biol. 2018 Sep;150(3):245-253. doi: 10.1007/s00418-018-1690-9. Epub 2018 Jul 7. Review. PubMed PMID: 29982846.

5: Tabrizi R, Ostadmohammadi V, Lankarani KB, Peymani P, Akbari M, Kolahdooz F, Asemi Z. The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2018 May 24;17(1):123. doi: 10.1186/s12944-018-0779-4. Review. PubMed PMID: 29793496; PubMed Central PMCID: PMC5968598.

6: Uchida K, Nakazawa M, Yamagishi C, Mikoshiba K, Yamagishi H. Inositol Trisphosphate Receptors in the Vascular Development. 2016 Jun 25. In: Nakanishi T, Markwald RR, Baldwin HS, Keller BB, Srivastava D, Yamagishi H, editors. Etiology and Morphogenesis of Congenital Heart Disease: From Gene Function and Cellular Interaction to Morphology [Internet]. Tokyo: Springer; 2016. Chapter 32. Available from PubMed PMID: 29787154.

7: Guo X, Guo S, Miao Z, Li Z, Zhang H. Myo-inositol lowers the risk of developing gestational diabetic mellitus in pregnancies: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. J Diabetes Complications. 2018 Mar;32(3):342-348. doi: 10.1016/j.jdiacomp.2017.07.007. Epub 2017 Jul 21. Review. PubMed PMID: 29325728.

8: Ando H, Kawaai K, Bonneau B, Mikoshiba K. Remodeling of Ca(2+) signaling in cancer: Regulation of inositol 1,4,5-trisphosphate receptors through oncogenes and tumor suppressors. Adv Biol Regul. 2018 May;68:64-76. doi: 10.1016/j.jbior.2017.12.001. Epub 2017 Dec 20. Review. PubMed PMID: 29287955.

9: Egorova PA, Bezprozvanny IB. Inositol 1,4,5-trisphosphate receptors and neurodegenerative disorders. FEBS J. 2017 Dec 18. doi: 10.1111/febs.14366. [Epub ahead of print] Review. PubMed PMID: 29253316.

10: Zheng X, Lin D, Zhang Y, Lin Y, Song J, Li S, Sun Y. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (Baltimore). 2017 Dec;96(49):e8842. doi: 10.1097/MD.0000000000008842. Review. PubMed PMID: 29245250; PubMed Central PMCID: PMC5728865.

11: Wickner RB, Edskes HK, Bezsonov EE, Son M, Ducatez M. Prion propagation and inositol polyphosphates. Curr Genet. 2018 Jun;64(3):571-574. doi: 10.1007/s00294-017-0788-2. Epub 2017 Dec 14. Review. PubMed PMID: 29243174; PubMed Central PMCID: PMC5949079.

12: Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017 Nov 29;11:CD003053. doi: 10.1002/14651858.CD003053.pub6. Review. PubMed PMID: 29183107.

13: Dinicola S, Minini M, Unfer V, Verna R, Cucina A, Bizzarri M. Nutritional and Acquired Deficiencies in Inositol Bioavailability. Correlations with Metabolic Disorders. Int J Mol Sci. 2017 Oct 20;18(10). pii: E2187. doi: 10.3390/ijms18102187. Review. PubMed PMID: 29053604; PubMed Central PMCID: PMC5666868.

14: Scioscia M. D-chiro inositol phosphoglycans in preeclampsia: Where are we, where are we going? J Reprod Immunol. 2017 Nov;124:1-7. doi: 10.1016/j.jri.2017.09.010. Epub 2017 Sep 28. Review. PubMed PMID: 28982033.

15: Saiardi A, Azevedo C, Desfougères Y, Portela-Torres P, Wilson MSC. Microbial inositol polyphosphate metabolic pathway as drug development target. Adv Biol Regul. 2018 Jan;67:74-83. doi: 10.1016/j.jbior.2017.09.007. Epub 2017 Sep 22. Review. PubMed PMID: 28964726.

16: Jung JY, Ried MK, Hothorn M, Poirier Y. Control of plant phosphate homeostasis by inositol pyrophosphates and the SPX domain. Curr Opin Biotechnol. 2018 Feb;49:156-162. doi: 10.1016/j.copbio.2017.08.012. Epub 2017 Sep 8. Review. PubMed PMID: 28889038.

17: Mendoza N, Pérez L, Simoncini T, Genazzani A. Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials. Reprod Biomed Online. 2017 Nov;35(5):529-535. doi: 10.1016/j.rbmo.2017.07.005. Epub 2017 Jul 14. Review. PubMed PMID: 28756130.

18: Orrù B, Circo R, Logoteta P, Petousis S, Carlomagno G. Finding the best therapeutic approach for PCOS: the importance of inositol(s) bioavailability. Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):83-88. Review. PubMed PMID: 28724181.

19: Colone M, Calcabrini A, Unfer V, Stringaro A. Contribution of electron microscopy to study in vitro inositol effects on human spermatozoa. Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):4-9. Review. PubMed PMID: 28724179.

20: Condorelli RA, La Vignera S, Mongioì LM, Vitale SG, Laganà AS, Cimino L, Calogero AE. Myo-inositol as a male fertility molecule: speed them up! Eur Rev Med Pharmacol Sci. 2017 Jun;21(2 Suppl):30-35. Review. PubMed PMID: 28724176.